文献速递血栓与止血

静脉血栓栓塞的种族差异:管理启示与行动呼吁

Ethnoracial variations in venous thrombosis: Implications for management, and a call to action.
PubMed 文献 · J Thromb Haemost · 2020-11-20

静脉血栓栓塞(VTE)仍是重要心血管病致死原因,不同种族群体症状性VTE风险存在临床相关差异。遗传性易栓症模式及社会因素、医疗可及性、疾病意识差异导致VTE结局差异,包括致命事件更高。VTE防治临床试验绝大多数受试者为白人,限制了非白人族群药物差异影响的理解,需增加多样性参与。

要点

  • 不同种族群体症状性VTE风险存在临床相关差异。
  • 遗传性易栓症模式及社会因素影响VTE结局差异。
  • VTE临床试验受试者以白人为主,需增加多样性参与。

核心结论

  • 不同种族群体症状性VTE风险存在临床相关差异,需增加临床试验多样性以优化非白人群体VTE防治。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 不同种族群体症状性VTE风险存在临床相关差异。
  • 已知遗传性易栓症模式可能影响维生素K拮抗剂或直接口服抗凝药相关大出血风险。
  • 社会因素、医疗可及性差异和疾病意识差异导致VTE结局差异,包括致命事件更高。
  • VTE防治临床试验绝大多数受试者为白人,限制了非白人族群药物差异影响的理解。

临床怎么用

  • 应优先增加不同种族群体在VTE防治临床试验中的参与,尤其是VTE负担重或抗凝出血并发症风险高的群体。
  • 需患者、研究者和监管机构倡导以确保多样性入组,为优化非白人群体VTE防治提供临床决策依据。

局限性

  • VTE防治临床试验受试者以白人为主,限制了对非白人族群药物差异影响的理解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite decades of improvement in its diagnosis and management, venous thromboembolism (VTE) remains a significant cause of cardiovascular morbidity and mortality. Clinically relevant differences exist in the risk of symptomatic VTE among ethnoracial groups. Underlying these differences in rates of VTE are patterns of known genetic thrombophilias, which may also influence the risks of major bleeding related to vitamin K antagonists or direct oral anticoagulants. In addition, social factors, differential access to care, and disease awareness differ between ethnoracial groups, which contributes to disparities in VTE outcomes that include higher fatal events. The vast majority of participants included in clinical trials for the prevention and treatment of VTE have been White Caucasian, which limits our understanding of the differential impact of these agents in non-White ethnoracial groups. Increasing the participation in clinical trials of diverse ethnoracial groups should be a priority, especially those groups who are disproportionately affected by the burden of VTE, or possible bleeding complications when exposed to anticoagulants. Advocacy by patients, researchers, and regulatory bodies is crucial to ensure adequate enrolment of diverse ethnoracial groups in order to best inform clinical decisions to optimize VTE prevention and treatment for non-White populations.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Xu Y, Siegal DM, Anand SS, et al. Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. J Thromb Haemost. 2020. PMID: 33078911. doi:10.1111/jth.15140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。